Modality
Gene Editing
MOA
PI3Ki
Target
FcRn
Pathway
Proteasome
MCC
Development Pipeline
Preclinical
Mar 2020
→ Jun 2031
PreclinicalCurrent
NCT08647245
1,749 pts·MCC
2020-03→2031-06·Terminated
1,749 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-06-155.2y awayInterim· MCC
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
Preclinical
Termina…
Catalysts
Interim
2031-06-15 · 5.2y away
MCC
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08647245 | Preclinical | MCC | Terminated | 1749 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| Sovafutibatinib | Moderna | Approved | FcRn |